Fairvalue-Calculator Fairvalue-Calculator
EN DE

Palisade Bio, Inc (PALI) Fair Value & Analysis

Healthcare · US · Market cap $325M

Price$1.94
Fair Value$3.35
Upside+72.7%
Quality95/100
Evidence: Low Range $2.52 – $4.19

Fair value as of: Jun 24, 2026

Analysis

Palisade Bio, Inc (PALI) currently trades at $1.94, while our model-based Fair Value estimate is $3.35 — implying the stock looks roughly 72.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Palisade Bio, Inc (PALI) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $3.35 versus a price of $1.94 — about +73% (undervalued). Model-based estimate, not financial advice.
What is the fair value of PALI?
Our 21-model fair value for Palisade Bio, Inc is $3.35 (as of Jun 24, 2026), built from audited fundamentals. The current price is $1.94.
What is the quality score of PALI?
Palisade Bio, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.